Company Overview and News

to your dashboard

Headline News

5 Big Biotech Stocks To Buy In 2018

2018-01-17 investorplace
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal. These are the ones that live or die by the FDA and clinical trials. (133-0)

Incyte: This ROTY Contender Is On Sale

2018-01-17 seekingalpha
I remind readers of key reasons I believe shares are undervalued and catalysts to look forward to. (71-0)

Discard These 4 Toxic Stocks or Sell Short for Profit

2018-01-17 zacks
The secret behind successful investing is the proper identification of overhyped toxic stocks and the correctly priced ones. However, it is not easy to accurately pinpoint toxic stocks and abandon them at the right time to make some gains at the end. Overblown toxic stocks are usually susceptible to outside shocks and loaded with a huge amount of debt. Also, the price of toxic stocks is unrealistically high. (37-0)

Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News

2018-01-17 zacks
Acquisitions once again remained in focus this week with Celgene (CELG - Free Report) rumored to be in talks with Juno (JUNO - Free Report) regarding a possible deal. Recap of the Week’s Most Important Stories Juno Soars on Acquisition Rumors: Juno’s shares skyrocketed on reports that Celgene is interested in acquiring the immuno-oncology focused company. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. (376-1)

ROTY Edition 1 Volume 70: A Solid Start To January And Thoughts On Taking Profits

2018-01-16 seekingalpha
I provide a case study of taking profits and also explain the importance of tracking your win rate to readers. (103-0)

Concert Pharmaceuticals Plunges on Patent Petition Setback

2018-01-15 zacks
Shares of Concert Pharmaceuticals, Inc. (CNCE - Free Report) plunged more than 25%, following the announcement that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has refused to grant the company a Post Grant Review petition in a dispute related to Incyte Corporation’s (INCY) ‘335 patent. (72-0)

4 ETFs Set to Surge in Q4 Earnings

2018-01-15 zacks
The fourth-quarter earnings season is expected to be strong, with earnings growth likely to pick up and continue accelerating after dipping in the preceding quarter. The S&P 500 index is anticipated to see earnings growth of 9.2% and revenue growth of 7%. The market is also at record levels, scaling series of highs at the start of the year. The forecast compares favorably with Q3 earnings growth of 6. (190-1)

Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day

2018-01-13 seekingalpha
Puma plans to modify labeling in its European marketing application for its breast cancer candidate neratinib. (254-7)

The Toxicity Of Geron's Imetelstat May Lead To Accelerated FDA Approval

2018-01-12 seekingalpha
Median survival for patients taking Imetelstat may already exceed double and may soon exceed triple the expected timeline for patients admitted into the iMbark trial. (53-6)

Incyte: Low Expectations, Great Growth, Looks Appealing

2018-01-12 seekingalpha
The combination of rapid growth and a 40% pullback from 2017 highs creates sales multiples that have collapsed. (13-0)

Thursday’s Biggest Winners and Losers in the S&P 500

2018-01-11 247wallst
Thursday was a strong day for the U.S. markets, with all three of the major exchanges hitting all-time highs yet again. Earnings season is just around the corner, and starting Friday we will finally get to see if the fundamentals are backing up this rally. Crude oil has seen a strong week so far and is holding above the $63 mark. The S&P 500 sectors were mostly positive. The best performing sector were energy, materials, and industrials, up 2%, 1. (11-0)

How biotech CEO John Hood turned failed Sanofi drug into multibillion deal

2018-01-09 livemint
San Francisco: In April 2016, John Hood went and told his wife that he had put down a quarter million dollars of their money to try and buy back a drug he’d helped invent, after it had failed in the hands of French drugmaker Sanofi. (63-0)

Celgene's Deal Won't Move the Dial - Bloomberg Gadfly

2018-01-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (63-0)

Biotech Forum Daily Digest For Jan. 8th

2018-01-08 seekingalpha
The biotech sector had a solid start to 2018, as did the overall market. The sector is selling off to start this week, however. (356-2)

CUSIP: 45337C102